2023-07-07 00:00:23
Each year, just over 29,000 cases and 7,000 deaths from breast cancer are reported in Mexico.
In 2006 it became the leading cause of death from a malignant tumor in women in our country.
Cofepris authorized 20 new medications, of which four are new molecules: one for the treatment of breast cancer, an antibiotic, eye drops, and a drug to treat dyslipidemia.
Tumors remain the second cause of mortality worldwide and especially breast cancer It is one of the most serious problems. Only during 2020, 2.2 million new cases were registered globally. While one of the biggest drawbacks is that more than 80% are diagnosed in advanced stages.
For its part, Mexico is no stranger to this situation. Each year, just over 29,000 cases and 7,000 deaths of this neoplasm are reported. While in 2006 it became the leading cause of death from a malignant tumor in women. But it is also a disease that not only affects one person but entire families.
However, beyond prevention and timely examinations for its detection, one should also think of women who already have breast cancer. For this sector of the population it is essential to have pharmacological options and that is why today one more is being added.
All part of the recent announcement of the Federal Commission for the Protection against Sanitary Risks (Cofepris) with which 125 health supplies were authorized. The objective is to expand and guarantee safe access to effective and quality medicines and medical devices.
New drugs approved
Of the more than 100 new health registrations, 20 correspond to drugs, of which four are new molecules: one for breast cancer treatment, an antibiotic, eye drops and a drug to treat dyslipidemia.
In addition, as part of the commitment of this health agency to the health of the population, eight clinical trials were authorized. Of these, three are protocols for cancer and one for hepatitis B virus treatment.
Cofepris authorizes a new drug for the treatment of breast cancer. The latest Fortnightly Report on Therapeutic Expansion reports the authorization of 125 safe, effective and quality health supplies ????????????. #CofeprisProtects You #CofeprisTransparente… pic.twitter.com/BNbb6VLWl5
— COFEPRIS (@COFEPRIS) July 6, 2023
Regarding the new supply of medical devices, a total of 97 were authorized. Of these, 37 correspond to devices dedicated to medical care. For example, biliary dilatation catheter, coronary dilation catheter, left ventricular assist device, and synthetic vascular graft.
There are also 37 medical pieces of equipment, including: device and accessories for soft tissue biopsy, maternal-fetal monitor, video colonoscope and video endoscope, as well as 23 diagnostic devices such as liver function tests, glycosylated hemoglobin, blood coagulation tests and detection of hepatitis B.
Mexico has enough drugs against cancer
On the other hand, the Undersecretary of Integration and Development of the Health Sector of the Ministry of Health (SSa), Juan Antonio Ferrer Aguilar, affirmed that Mexico has an assured supply of oncological drugs for the remainder of this 2023 and for 2024.
He mentioned that drug supply orders were also requested from the federal entities for the remainder of 2023, and as of January 1, 2024, the IMSS-Bienestar will be in charge of the process.
The official clarified that the transfer of medical services from the states to the federation in no way affects the continuity of the treatments received by cancer patients.
Also read:
Biological bank helps identify the risk of breast cancer: This is how it works
Cofepris approves a new therapy against metastatic breast cancer that reduces progression by 64%
CIMA Foundation, a pillar in supporting women with breast cancer
#Cofepris #authorizes #medication